Biotech stocks experienced a significant decline following the Federal Reserve's announcement of a slower pace for interest rate cuts. The Fed's projection of only two rate cuts in 2025 due to persistent inflation and economic factors contributed to the market downturn. While the Dow, S&P, and Nasdaq also fell, the biotech index XBI and SPBIOS plummeted nearly 5%, and the Nasdaq biotechnology index dropped over 4.2%.
Experts attribute this sensitivity to interest rates due to the sector's continuous funding requirements. This news presents a challenge to biotech startups, as previous rate hikes in 2022 and 2023 led to decreased investments. While recent rate cuts have spurred a slight increase in investment, the current cycle is driven more by fear of missing out (FOMO) than by innovation. To break this cycle, more initial public offerings (IPOs) and mergers and acquisitions (M&A) are needed to provide investors with returns and liquidity, stabilizing the biotech market. However, sustained higher interest rates could impede these activities, making it harder for new startups to thrive and innovate
Россия Последние новости, Россия Последние новости
Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей
Источник: Investingcom - 🏆 450. / 53 Прочитайте больше »
Источник: Investingcom - 🏆 450. / 53 Прочитайте больше »
Источник: CNBC - 🏆 12. / 72 Прочитайте больше »
Источник: NBCNewYork - 🏆 270. / 63 Прочитайте больше »
Источник: Investingcom - 🏆 450. / 53 Прочитайте больше »
Источник: Investingcom - 🏆 450. / 53 Прочитайте больше »